A recent research unveils this information. - Injection for shedding pounds is beneficial in treating kidney problems.
In a recent international study on 3533 patients, researchers collaborated with Novo Nordisk, a Danish pharmaceutical company and the manufacturer of Ozempic, to examine the effects of semaglutide in preventing severe kidney damage or cardiovascular illness in individuals with type 2 diabetes and chronic kidney disease. The study proceeded for almost three and a half years.
Semaglutide, the main component of Ozempic, is typically recognized for its weight loss properties. It aids in glucose regulation, resulting in prolonged feelings of fullness. This eventually leads to weight loss, provided the medication is consistently administered.
The trial participants, who received 1.0 mg of semaglutide every week, displayed a 24 percent lower likelihood of suffering from kidney damage and death related to cardiovascular and renal conditions, compared to those given a placebo.
Universität Süd Wales Professor Vlado Perkovic, the lead investigator of the study, stated, "The usage of semaglutide in individuals with type 2 diabetes and chronic kidney disease can significantly reduce the likelihood of severe kidney damage, the chance of cardiovascular disease, and overall longevity."
Chronic kidney disease, impacting over 800 million people globally, is particularly common in individuals with type 2 diabetes.
One advantageous aspect of Ozempic is its ability to lower the likelihood of heart attacks, strokes, and liver cancer. Additionally, this weight-management drug has reportedly promoted fertility and reduced suicide rates.
However, several adverse effects have been documented, such as nausea, vomiting, and headaches. While these negative consequences might prevail, the positive outcomes overshadow them.
Read also:
- Does the SVolt factory in Saarland face stability issues?
- Halle transfers Halili from Jena.
- Greens discuss using taxpayer funds as if playing cards.
- Knorr holds an edge at home against an intimidated rival.
Source: symclub.org